title: Plerixafor.
authors.forename: John F
authors.initials: JF
authors.lastname: DiPersio
authors.forename: Geoffrey L
authors.initials: GL
authors.lastname: Uy
authors.forename: Uma
authors.initials: U
authors.lastname: Yasothan
authors.forename: Peter
authors.initials: P
authors.lastname: Kirkpatrick
mesh_terms: D000818:Animals; D001596:Benzylamines; D000080027:Cyclams; D017277:Drug Approval; D004359:Drug Therapy, Combination; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation; D006571:Heterocyclic Compounds / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000628:therapy; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000628:therapy; D016032:Randomized Controlled Trials as Topic; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors*
chemical_list: D001596:Benzylamines; D000080027:Cyclams; D006571:Heterocyclic Compounds; D019718:Receptors, CXCR4; D016179:Granulocyte Colony-Stimulating Factor; C088327:plerixafor